Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H3N2 M2SR Influenza Vaccine in Healthy Adults
NCT02822105Phase 1Completed
- Sponsor
- FluGen
- Start
- Jun 2016
- Primary completion
- Apr 2017
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in influenza comparing H3N2 M2SR with Placebo (2 arms). Primary endpoint: Frequency and severity of local and systemic adverse events at 180 days. Started Jun 2016; status: completed.
02
Drugs
M2SR H3N2 influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02822105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02822105.